TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02886676

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spirulina capsules
Description: Spirulina capsules 2gm daily for 1 month
Study: NCT00935857

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single Balloon Colonoscopy
Description: Use of the single balloon enteroscopy system (enteroscope and balloon-overtube) to complete colonoscopy.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Colonoscopy
Description: Use of the standard adult colonoscope to complete colonoscopy.
Study: NCT03261180

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional Intervention
Description: Receive Nestle Impact AR
Study: NCT02090868

Intervention type: OTHER
Intervention: Oral Intake Screening Tool
Description: A screening tool developed from a literature review and expert opinion. It will be used by nurses to assess patients receiving non-invasive ventilation ability to eat and drink orally and suggest what actions should be taken if they are unable to do so
Study: NCT03028350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifetroban Oral Capsule
Description: Subjects will be treated with oral ifetroban daily for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Capsule
Description: Subjects will be treated with oral placebo daily for 8 weeks
Study: NCT02156531

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Administered, Active Cognitive Bias Modification (CBM)
Description: Cognitive Bias Modification (CBM) is a novel treatment delivered via a downloadable computer program. CBM retrains individuals' attention away from negative/threatening stimuli and toward more balanced attention toward neutral stimuli.
Study: NCT02886676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spirulina capsules
Description: Spirulina capsules 2gm daily for 1 month
Study: NCT02144805

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suturing in a single layer
Description: The procedure define the use of one single suture for closure of the uterine incision following cesarean section.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suturing in two layer
Description: The procedure define the use of two sutures for closing the uterine incision following cesarean section
Study: NCT02678780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Study: NCT02159820

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Decitabine (DTC Arm)
Description: Patients in DTC arm will receive lower-dose decitabine (7 mg/m2) administered intravenously within 1 hour for a consecutive 5 days, followed by TC regimen on day 6.
Study: NCT02156531

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Administered, Active Cognitive Bias Modification (CBM)
Description: Cognitive Bias Modification (CBM) is a novel treatment delivered via a downloadable computer program. CBM retrains individuals' attention away from negative/threatening stimuli and toward more balanced attention toward neutral stimuli.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Self-Administered, minimally effective attention-control version of the CBM program
Description: Identical to the active CBM program except that during the presentation of the trails where a disgusted face is present, the probe will appear with equal frequency (50-50) in the position of disgusted or neutral face. This, the balanced (random) presentation of the probe in this condition is not designed to explicitly train attention away from threat and toward neutral stimuli, in contrast to the active version of CBM.
Study: NCT02972372

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CRT
Description: Drug: Capecitabine(Aibin) capecitabine(Aibin)：625mg/m2, bid d1-5; q1w, po,5 weeks in total~Other Names:~Aibin Drug: Oxaliplatin(Aiheng) Oxaliplatin(Aiheng)：65mg/m2，d1，8, 22, 29,I.V.~Other Names:~Aiheng cisplatin: 75mg/m2 d1，29 or d1, 29, 57, 85. 5-Fu：750mg/m2 CIV24h d1-4，d29-32 or d1-4，d29-32, d57-60, d85-88.~Radiation: Radiotherapy concurrent radiotherapy：IMRT radiotherapy 50Gy in total，2 Gy/d，5d/w，Until disease progression or unacceptable toxicity

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgery
Description: The patients randomized to receive either standard esophagectomy will have the operation performed in an open manner with two-field lymphadenectomy
Study: NCT04547413

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: STI/HIV Intervention Behavioral Intervention Program
Description: In addition to standard of care STi/HIV counselling, participants in the intervention arm will also attend a 2-hour educational class and will receive monthly SMS/text messages to reinforce the content of the class.
Study: NCT04633460

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone ester
Description: A nutraceutical ketone ester (KE), (R)-3-hydroxybutyl (R)-3-hydroxybutyrate which provides systemic ketosis
Study: NCT01244334

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Difluprednate ophthalmic emulsion 0.05%
Description: Difluprednate ophthalmic emulsion 0.05%: 29 days total, total of 7 drops prior to surgery, and 3 more following surgery while at the surgery center, then Q2H on day of surgery, then QID for 1 week, then BID for 1 week, then stop.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone acetate 1%
Description: Prednisolone acetate 1% : 29 days total, total of 7 drops prior to surgery, and 3 more following surgery while at the surgery center, then Q2H on day of surgery, then QID for 1 week, then BID for 1 week, then stop.
Study: NCT01993329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant 50 mg
Description: Gefapixant 50 mg tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant 50 mg
Description: Gefapixant 50 mg tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant 50 mg
Description: Gefapixant 50 mg tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant 50 mg
Description: Gefapixant 50 mg tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant 50 mg
Description: Gefapixant 50 mg tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant 50 mg
Description: Gefapixant 50 mg tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant 300 mg
Description: Gefapixant 300 mg tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant 300 mg
Description: Gefapixant 300 mg tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant 300 mg
Description: Gefapixant 300 mg tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant 300 mg
Description: Gefapixant 300 mg tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant 300 mg
Description: Gefapixant 300 mg tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant 300 mg
Description: Gefapixant 300 mg tablet administered orally
Study: NCT04633460

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo drink
Description: KE free placebo drink
Study: NCT01993329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to mimic 50 mg tablets
Description: Sugar pill manufactured to mimic gefapixant 50 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to mimic 50 mg tablets
Description: Sugar pill manufactured to mimic gefapixant 50 mg tablets
Study: NCT02159820

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel and Carboplatin (TC Arm)
Description: The TC arm consisted of paclitaxel 150 mg/m2 administered intravenously (IV) over 3 hours followed by carboplatin (area under the curve \[AUC\] 5) administered by IV over 30 to 60 minutes both on day 1 of a 3-week schedule. Dose reductions were allowed depending on hematologic or nonhematologic toxicity, as follows: carboplatin AUC4; paclitaxel 135 mg/m2. Patients who achieved partial remission after six cycles could receive additional cycles on their physicians' discretion.
Study: NCT02208336

Intervention type: OTHER
Intervention: medical chart review
Description: Ancillary studies
Study: NCT03410823

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PUSH
Description: Strength components of the muscle performance intervention are performed using a portable progressive resistive exercise device (Shuttle® MiniPress, Contemporary Design Company, P.O. Box 5089, Glacier, Washington 98244). Muscle performance focuses on bilateral hip extensors, hip abductors, knee extensors, and plantar flexors. Balance and strength are addressed with additional exercises performed while standing. The endurance intervention begins with 2-3 minutes of continuous upper and lower extremity active range of motion (AROM) with the participant sitting in order to increase the participants' heart rate (HR) or exertion closer to the target zone. The participant is then asked to walk on level surfaces and/or up and down steps to keep the HR within the training zone for 20 minutes.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein
Description: Participants will receive a whey-based protein supplement in the form of a powder containing 27.6g of protein. This dose induces maximum muscle protein synthesis post-exercise. Participants will mix the supplement in 8 oz of water (or other beverage) or soft food (e.g., yogurt, soup) and consume immediately following each exercise session with the study PT. On days when they do not have a physical therapy visit with the study PT, participants will be instructed to take the supplement at the meal time closest to the time of scheduled PT visits to maintain regular daily dosing schedule.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutrition
Description: Participants receive 2000 IU vitamin D3, 600 mg calcium, and a multivitamin daily for the duration of the study. Nutritional counseling is also provided. Participants are screened at baseline to assess nutritional risk using the Mini Nutritional Assessment-Short Form and contacted by a registered dietician (RD) within 7 days of baseline testing Those who score ≤7 (malnourished) and participants with baseline serum albumin 2.5-3.5 g/dl receive a visit from an RD with follow-up a week later. Participants who score 8-11 (at risk of malnutrition) and have serum albumin level \>3.5 g/dl receive a phone call from the RD and may receive an in-person visit if warranted. Those screening in the normal range (12-14) and have serum albumin level \>3.5 g/dl receive a phone call from the RD. Weight is monitored every 4 weeks. Those who lose 2% or more body weight receive a call from the RD. Those who lose 5% or more body weight between baseline and follow-up may be referred to an RD.
Study: NCT03022656

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Brace system

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Brace system
Study: NCT01995370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clopidogrel
Description: Clopidogrel (50mg or 75mg) will be orally administered once daily.The treatment period will begin with the first visit of the first subject and end one year after the first visit of the last subject.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel
Description: Clopidogrel (50mg or 75mg) will be orally administered once daily.The treatment period will begin with the first visit of the first subject and end one year after the first visit of the last subject.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cilostazol
Description: Cilostazol (100mg twice daily) will be orally administered. The treatment period will begin with the first visit of the first subject and end one year after the first visit of the last subject.
Study: NCT00684502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2066
Description: Oral solution administered orally once per day on day 1, and then day 3 through to day 12. Specific dose depends on dose panel.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally as a solution once per day on day 1, and then day 3 through to day 12.
Study: NCT02365896

Intervention type: PROCEDURE
Group type: OTHER
Intervention: TLDG or LADG
Study: NCT01993329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to mimic 50 mg tablets
Description: Sugar pill manufactured to mimic gefapixant 50 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to mimic 50 mg tablets
Description: Sugar pill manufactured to mimic gefapixant 50 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to mimic 50 mg tablets
Description: Sugar pill manufactured to mimic gefapixant 50 mg tablets
Study: NCT04890132

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VOR precision training
Description: Subjects are rotated in yaw using a pseudo-random sum of sines motion (0.5 - 2.0 Hz), view a monitor 1 m away, and are instructed to move their avatar through a maze using a joystick. The size of the maze becomes smaller in real-time when they are successful so that the patient is at the limit of their acuity. This task requires patients to optimize dynamic visual acuity to threshold-level images while rotating. We predict that VOR precision will gradually improve during training and that after training VOR precision will be better than the pre-training data. The sham task is as above but the acuity required to see the maze will set at a much larger level so baseline visual precision will be adequate to perform the task easily.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VOR precision training
Description: Subjects are rotated in yaw using a pseudo-random sum of sines motion (0.5 - 2.0 Hz), view a monitor 1 m away, and are instructed to move their avatar through a maze using a joystick. The size of the maze becomes smaller in real-time when they are successful so that the patient is at the limit of their acuity. This task requires patients to optimize dynamic visual acuity to threshold-level images while rotating. We predict that VOR precision will gradually improve during training and that after training VOR precision will be better than the pre-training data. The sham task is as above but the acuity required to see the maze will set at a much larger level so baseline visual precision will be adequate to perform the task easily.
Study: NCT00347048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study: NCT03390244

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foldable Capsular Vitreous Body Implant
Description: Vitrectomy augmented with the implantation of the FCVB implant
Study: NCT04201015

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heart rate optimisation using force frequency data
Description: Programming heart rate rise according to the force frequency relationship

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Heart rate optimisation using force frequency data
Description: Programming heart rate rise according to the force frequency relationship
Study: NCT02570854

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSJ137
Description: Starting dose is 0.010 mg/kg and dose escalation will proceed with semi-log increase steps to a maximum dose level 10 mg/kg. Subjects receive the treatment via up to 30 minutes intravenous infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be dosed with a matching placebo (vehicle control) via up to 30 minutes intravenous infusion.
Study: NCT00139815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fondaparinux
Description: fondaparinux 2.5 mg, s.c. injection once daily x 8 days or Hospital Discharge if earlier and placebo-enoxaparin 1mg/kg s.c. injection twice daily x 2-8 days or until clinically stable

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: enoxaparin
Description: enoxaparin 1mg/kg s.c. injection twice daily x 2 to 8 days
Study: NCT00991692

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapy services (ACQUIREc Therapy)
Description: Dosage levels that are associated with the efficacy of intensive therapeutic services provided by OT and PT professionals.
Study: NCT01044134

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary counseling
Description: Participants will receive personalized dietary counseling to promote behavior change

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary counseling
Description: Participants will receive personalized dietary counseling to promote behavior change
Study: NCT02490800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisavanbulin Phase 1 dose escalation portion
Description: Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily in the dose range of 2 to 35 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisavanbulin Phase 2a expansion portion
Description: Recommended Phase 2 dose (RP2D) of 25 mg/day lisavanbulin hard capsules containing 5 mg study drug was administered once daily.
Study: NCT01993329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to mimic 50 mg tablets
Description: Sugar pill manufactured to mimic gefapixant 50 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to mimic 300 mg tablets
Description: Sugar pill manufactured to mimic gefapixant 300 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to mimic 300 mg tablets
Description: Sugar pill manufactured to mimic gefapixant 300 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to mimic 300 mg tablets
Description: Sugar pill manufactured to mimic gefapixant 300 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to mimic 300 mg tablets
Description: Sugar pill manufactured to mimic gefapixant 300 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to mimic 300 mg tablets
Description: Sugar pill manufactured to mimic gefapixant 300 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to mimic 300 mg tablets
Description: Sugar pill manufactured to mimic gefapixant 300 mg tablets
Study: NCT01844700

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ziprasidone
Description: random assignment to ZIP (20-160mg/d, bid dosing)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aripiprazole, quetiapine, or risperidone
Description: random assignement to Usual Care antipsychotic UC antipsychotic (aripiprazole 2-30mg/d, quetiapine 25-800mg/d or risperidone 0.1-8mg/d)
Study: NCT00854763

Intervention type: DRUG
Intervention: olmesartan
Description: olmesartan
Study: NCT01270672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3,4-Methylenedioxymethamphetamine
Description: 125 mg per os, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carvedilol
Description: 50 mg per os, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: capsules identical to MDMA or carvedilol
Study: NCT03711838

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine
Description: N-Acetylcysteine in a powder form diluted in a 250 ml drink containing 248 ml water and 2 ml of natural, non-caloric, flavoring-sweetener containing sucralose.
Study: NCT00960440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: Oral tablets administered at 5 mg BID daily for 6 months during the double-blind, placebo-controlled period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: Oral tablets administered at 10 mg BID daily for 6 months during the double-blind, placebo-controlled period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo tablets administered BID daily during the first 3 months of the double-blind, study period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CP-690,550
Description: Oral tablets administered at 5 mg BID daily during the second 3 months of the double-blind, study period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo tablets administered BID daily during the first 3 months of the double-blind, placebo-controlled period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CP-690,550
Description: Oral tablets administered at 10 mg BID daily during the second 3 months of the double-blind, study period.
Study: NCT01935908

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levetiracetam
Study: NCT03125746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LXI-15029
Description: The investigational product for this study is LXI-15029 capsule, which can be administered orally and the specification included 10 mg and 50 mg. There will be about 6 cohorts during the monotherapy period. LXI-15029 capsules will be administered in a therapeutic cycle of 28 days twice a day orally. The patients will be given LXI-15029 continuously, in a therapeutic cycle of 28 days. Patients will continue therapy with LXI-15029 if good safety and tolerability were assessed by investigators after 1 cycle treatment. The treatment will continue until progression or occurrence of unmanageable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LXI-15029+Exemestane
Description: The combined drug in the combined therapy period of this study (investigational product) is Exemestane tablet (specification 25 mg). Exemestane should be taken at similar time every day in case of multiple doses (Cycle 1 Day 1 to Cycl 1 Day 28). If one dose was missed (e.g., forgetting, vomiting, etc.), this dose could not be made up and should be administered at next scheduled time point. And the dose of LXI-15029 will be determinated by safety review committee after dose escalation
Study: NCT04221906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOS-475
Description: topical cream

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOS-475
Description: topical cream

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOS-475
Description: topical cream

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Active ingredient-free vehicle cream
Description: topical cream

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daivonex cream (calcipotriol 0.005%)
Description: topical cream

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betnesol-V cream (betamethasone 0.1%)
Description: topical cream